EREmilie Ronin

Emilie Ronin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emilie Ronin has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Benoit Laurent Salomon

    Sorbonne Université, Inserm U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France

    6 shared publications
  • Sylvie Grégoire

    Sorbonne Université, INSERM, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI)–Paris, F-75013 Paris, France

    4 shared publications
  • Jordane Divoux

    Centre d’Immunologie et des Maladies Infectieuses, Sorbonne Université, INSERM, CNRS , 75013 Paris

    3 shared publications
  • Martina Lubrano di Ricco

    Centre d’Immunologie et des Maladies Infectieuses, Sorbonne Université, INSERM, CNRS , 75013 Paris

    3 shared publications
  • Davi Collares

    Université Paris Descartes, Sorbonne Paris Cité, Laboratoire NF-κB, Différenciation et Cancer, Paris, France

    2 shared publications
  • Gilles Marodon

    Centre d’immunologie et des maladies infectieuses (CIMI), Inserm U1135, Sorbonne Université, CNRS, Paris, France

    2 shared publications

Latest Publications

  • Open Access

    Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival

    by Johanna C. Wagner, Emilie Ronin, Patrick Ho, Yani Peng, Qizhi Tang


  • Open Access

    Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance

    by Yannick D. Muller, Leonardo M.R. Ferreira, Emilie Ronin, Patrick Ho, Vinh Nguyen, Gaetano Faleo, Yu Zhou, Karim Lee, Kevin K. Leung, Nikolaos Skartsis, et al.

    Infusion of regulatory T cells (Tregs) engineered with a chimeric antigen receptor (CAR) targeting donor-derived human leukocyte antigen (HLA) is a promising strategy to promote transplant tolerance. Here, we describe an anti-HLA-A2 CAR (A2-CAR) generated by grafting the complementarity-determining regions (CDRs) of a human monoclonal anti-HLA-A2 antibody into the framework regions of the Herceptin 4D5 single-chain variable fragment and fusing it with a CD28-ζ signaling domain. The CDR-grafted A2-CAR maintained the specificity of the original antibody. We then generated HLA-A2 mono-specific human CAR Tregs either by deleting the endogenous T-cell receptor (TCR) via CRISPR/Cas9 and introducing the A2-CAR using lentiviral transduction or by directly integrating the CAR construct into the TCR alpha constant locus using homology-directed repair. These A2-CAR + TCR deficient human Tregs maintained both Treg phenotype and function in vitro . Moreover, they selectively accumulated in HLA-A2-expressing islets transplanted from either HLA-A2 transgenic mice or deceased human donors. A2-CAR + TCR deficient Tregs did not impair the function of these HLA-A2 + islets, whereas similarly engineered A2-CAR + TCR deficient CD4 + conventional T cells rejected the islets in less than 2 weeks. A2-CAR + TCR deficient Tregs delayed graft-versus-host disease only in the presence of HLA-A2, expressed either by co-transferred peripheral blood mononuclear cells or by the recipient mice. Altogether, we demonstrate that genome-engineered mono-antigen-specific A2-CAR Tregs localize to HLA-A2-expressing grafts and exhibit antigen-dependent in vivo suppression, independent of TCR expression. These approaches may be applied towards developing precision Treg cell therapies for transplant tolerance.


  • Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells

    by Emilie Ronin, Charlotte Pouchy, Maryam Khosravi, Morgane Hilaire, Sylvie Grégoire, Armanda Casrouge, Sahar Kassem, David Sleurs, Gaëlle H. Martin, Noémie Chanson, et al.

    CD4+Foxp3+ regulatory T (Treg) cells are central modulators of autoimmune diseases. However, the timing and location of Treg cell–mediated suppression of tissue-specific autoimmunity remain undefined. Here, we addressed these questions by investigating the role of tumor necrosis factor (TNF) receptor 2 (TNFR2) signaling in Treg cells during experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. We found that TNFR2-expressing Treg cells were critical to suppress EAE at peak disease in the central nervous system but had no impact on T cell priming in lymphoid tissues at disease onset. Mechanistically, TNFR2 signaling maintained functional Treg cells with sustained expression of CTLA-4 and Blimp-1, allowing active suppression of pathogenic T cells in the inflamed central nervous system. This late effect of Treg cells was further confirmed by treating mice with TNF and TNFR2 agonists and antagonists. Our findings show that endogenous Treg cells specifically suppress an autoimmune disease by acting in the target tissue during overt inflammation. Moreover, they bring a mechanistic insight to some of the adverse effects of anti-TNF therapy in patients. Significance Regulatory T (Treg) cells have been highlighted for their central function in limiting the severity of autoimmune diseases such as multiple sclerosis (MS). To date, the anatomical location and timing of this Treg cell–mediated suppression are unknown. In this report, in a mouse model of MS, we demonstrate that Treg cells inhibit the pathogenic process directly in the central nervous system during established disease, rather than in the presymptomatic phase. This protective function requires the surface expression of TNF receptor 2 by Treg cells, as its genetic ablation or antibody-mediated blockade worsens disease symptoms. Our data reveal a unique function of Treg cells in autoimmunity and highlight TNFR2 as a promising therapeutic target.


  • Regulatory T Cell Stability and Migration Are Dependent on mTOR

    by Romain Vallion, Jordane Divoux, Salomé Glauzy, Emilie Ronin, Yannis Lombardi, Martina Lubrano di Ricco, Sylvie Grégoire, Ivan Nemazanyy, Aurélie Durand, Delphine Fradin, et al.

    CD4+ Foxp3+ regulatory T cells (Treg) are essential to maintain immune tolerance, as their loss leads to a fatal autoimmune syndrome in mice and humans. Conflicting findings have been reported concerning their metabolism. Some reports found that Treg have low mechanistic target of rapamycin (mTOR) activity and would be less dependent on this kinase compared with conventional T cells, whereas other reports suggest quite the opposite. In this study, we revisited this question by using mice that have a specific deletion of mTOR in Treg. These mice spontaneously develop a severe and systemic inflammation. We show that mTOR expression by Treg is critical for their differentiation into effector Treg and their migration into nonlymphoid tissues. We also reveal that mTOR-deficient Treg have reduced stability. This loss of Foxp3 expression is associated with partial Foxp3 DNA remethylation, which may be due to an increased activity of the glutaminolysis pathway. Thus, our work shows that mTOR is crucial for Treg differentiation, migration, and identity and that drugs targeting this metabolism pathway will impact on their biology.


  • Open Access

    Regulatory T Cells Expressing Tumor Necrosis Factor Receptor Type 2 Play a Major Role in CD4+ T-Cell Impairment During Sepsis

    by Benjamin J Gaborit, Antoine Roquilly, Cédric Louvet, Abderrahmane Sadek, Benoit Tessoulin, Alexis Broquet, Cédric Jacqueline, Mickael Vourc’h, Tanguy Chaumette, Marie Chauveau, et al.

    Sepsis causes inflammation-induced immunosuppression with lymphopenia and alterations of CD4+ T-cell functions that renders the host prone to secondary infections. Whether and how regulatory T cells (Treg) are involved in this postseptic immunosuppression is unknown. We observed in vivo that early activation of Treg during Staphylococcus aureus sepsis induces CD4+ T-cell impairment and increases susceptibility to secondary pneumonia. The tumor necrosis factor receptor 2 positive (TNFR2pos) Treg subset endorsed the majority of effector immunosuppressive functions, and TNRF2 was particularly associated with activation of genes involved in cell cycle and replication in Treg, probably explaining their maintenance. Blocking or deleting TNFR2 during sepsis decreased the susceptibility to secondary infection. In humans, our data paralleled those in mice; the expression of CTLA-4 was dramatically increased in TNFR2pos Treg after culture in vitro with S. aureus. Our findings describe in vivo mechanisms underlying sepsis-induced immunosuppression and identify TNFR2pos Treg as targets for therapeutic intervention.


  • Open Access

    Tumor necrosis factor receptor family costimulation increases regulatory T‐cell activation and function via NF‐κB

    by Martina Lubrano di Ricco, Emilie Ronin, Davi Collares, Jordane Divoux, Sylvie Grégoire, Harald Wajant, Tomás Gomes, Yenkel Grinberg‐Bleyer, Véronique Baud, Gilles Marodon, et al.

    Several drugs targeting members of the TNF superfamily or TNF receptor superfamily (TNFRSF) are widely used in medicine or are currently being tested in therapeutic trials. However, their mechanism of action remains poorly understood. Here, we explored the effects of TNFRSF co‐stimulation on murine Foxp3+ regulatory T cell (Treg) biology, as they are pivotal modulators of immune responses. We show that engagement of TNFR2, 4‐1BB, GITR, and DR3, but not OX40, increases Treg proliferation and survival. Triggering these TNFRSF in Tregs induces similar changes in gene expression patterns, suggesting that they engage common signal transduction pathways. Among them, we identified a major role of canonical NF‐κB. Importantly, TNFRSF co‐stimulation improves the ability of Tregs to suppress colitis. Our data demonstrate that stimulation of discrete TNFRSF members enhances Treg activation and function through a shared mechanism. Consequently, therapeutic effects of drugs targeting TNFRSF or their ligands may be mediated by their effect on Tregs.


  • Open Access

    The NF-κB RelA Transcription Factor Is Critical for Regulatory T Cell Activation and Stability

    by Emilie Ronin, Martina Lubrano di Ricco, Romain Vallion, Jordane Divoux, Ho-Keun Kwon, Sylvie Grégoire, Davi Collares, Angéline Rouers, Véronique Baud, Christophe Benoist, et al.

    Regulatory T cells (Tregs) play a major role in immune homeostasis and in the prevention of autoimmune diseases. It has been shown that c-Rel is critical in Treg thymic differentiation, but little is known on the role of NF-κB on mature Treg biology. We thus generated mice with a specific knockout of RelA, a key member of NF-κB, in Tregs. These mice developed a severe autoimmune syndrome with multi-organ immune infiltration and high activation of lymphoid and myeloid cells. Phenotypic and transcriptomic analyses showed that RelA is critical in the acquisition of the effector Treg state independently of surrounding inflammatory environment. Unexpectedly, RelA-deficient Tregs also displayed reduced stability and cells that had lost Foxp3 produced inflammatory cytokines. Overall, we show that RelA is critical for Treg biology as it promotes both the generation of their effector phenotype and the maintenance of their identity.


  • Open Access

    Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology

    by Benoît L. Salomon, Mathieu Leclerc, Jimena Tosello, Emilie Ronin, Eliane Piaggio, José L. Cohen

    Tumor necrosis factor α (TNF) is a potent pro-inflammatory cytokine that has deleterious effect in some autoimmune diseases, which led to the use of anti-TNF drugs in some of these diseases. However, some rare patients treated with these drugs paradoxically develop an aggravation of their disease or new onset autoimmunity, revealing an immunosuppressive facet of TNF. A possible mechanism of this observation is the direct and positive effect of TNF on regulatory T cells (Tregs) through its binding to the TNF receptor type 2 (TNFR2). Indeed, TNF is able to increase expansion, stability, and possibly function of Tregs via TNFR2. In this review, we discuss the role of TNF in graft-versus-host disease as an example of the ambivalence of this cytokine in the pathophysiology of an immunopathology, highlighting the therapeutic potential of triggering TNFR2 to boost Treg expansion. We also describe new targets in immunotherapy of cancer, emphasizing on the putative suppressive effect of TNF in antitumor immunity and of the interest of blocking TNFR2 to regulate the Treg compartment.


  • Glucocorticoid-Induced Leucine Zipper Enhanced Expression in Dendritic Cells Is Sufficient To Drive Regulatory T Cells Expansion In Vivo

    by Joseph Calmette, Mehdi Ellouze, Thi Tran, Soumaya Karaki, Emilie Ronin, Francis Capel, Marc Pallardy, Françoise Bachelerie, Roman Krzysiek, Dominique Emilie, et al.

    Tolerance induction by dendritic cells (DCs) is, in part, mediated by the activation of regulatory T cells (Tregs). We have previously shown in vitro that human DCs treated with glucocorticoids (GCs), IL-10, or TGF-β upregulate the GC-Induced Leucine Zipper protein (GILZ). GILZ overexpression promotes DC differentiation into regulatory cells that generate IL-10–producing Ag-specific Tregs. To investigate whether these observations extend in vivo, we have generated CD11c-GILZhi transgenic mice. DCs from these mice constitutively overexpress GILZ to levels observed in GC-treated wild-type DCs. In this article, we establish that GILZhi DCs display an accumulation of Foxp3+ Tregs in the spleens of young CD11c-GILZhi mice. In addition, we show that GILZhi DCs strongly increase the Treg pool in central and peripheral lymphoid organs of aged animals. Upon adoptive transfer to wild-type recipient mice, OVA-loaded GILZhi bone marrow–derived DCs induce a reduced activation and proliferation of OVA-specific T cells as compared with control bone marrow–derived DCs, associated with an expansion of thymus-derived CD25+Foxp3+ CD4 T cells. Transferred OVA-loaded GILZhi DCs produce significantly higher levels of IL-10 and express reduced levels of MHC class II molecules as compared with OVA-loaded control DCs, emphasizing the regulatory phenotype of GILZhi DCs in vivo. Thus, our work demonstrates in vivo that the GILZ overexpression alone is sufficient to promote a tolerogenic mode of function in DCs.